News Image

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Provided By GlobeNewswire

Last update: Jun 4, 2025

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane”), with the acqusition of the R&D organization of Xbrane in Sweden and biosimilar candidate to Cimzia® (certolizumab pegol). All regulatory conditions have been fulfilled.

Read more at globenewswire.com

ALVOTECH SA

NASDAQ:ALVO (6/10/2025, 8:27:12 PM)

After market: 10.37 0 (0%)

10.37

-0.26 (-2.45%)



Find more stocks in the Stock Screener

Follow ChartMill for more